Kidney cancer: post-surgery sorafenib
0 Vues
• 06/26/23
0
0
Intégrer
administrator
Les abonnés
Tim Eisen, MBBChir, PhD, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, describes the rationale and methodology behind the SORCE trial (NCT00492258) and what have we learned at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.
Montre plus
Commentaires de Facebook
SORT BY-
Meilleures Commentaires
-
Derniers Commentaires